Raymond James Financial Inc. Takes $6.02 Million Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Raymond James Financial Inc. bought a new position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) during the fourth quarter, Holdings Channel reports. The fund bought 313,787 shares of the company’s stock, valued at approximately $6,015,000.

Other hedge funds have also modified their holdings of the company. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Viridian Therapeutics in the 3rd quarter valued at $208,000. Intech Investment Management LLC acquired a new position in shares of Viridian Therapeutics in the third quarter worth about $422,000. Charles Schwab Investment Management Inc. increased its position in shares of Viridian Therapeutics by 6.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 516,213 shares of the company’s stock worth $11,744,000 after acquiring an additional 32,292 shares in the last quarter. Algert Global LLC raised its holdings in shares of Viridian Therapeutics by 107.1% during the third quarter. Algert Global LLC now owns 114,913 shares of the company’s stock valued at $2,614,000 after acquiring an additional 59,420 shares during the period. Finally, Fisher Asset Management LLC lifted its position in shares of Viridian Therapeutics by 25.1% in the 3rd quarter. Fisher Asset Management LLC now owns 494,924 shares of the company’s stock valued at $11,260,000 after acquiring an additional 99,427 shares in the last quarter.

Viridian Therapeutics Trading Up 1.3 %

NASDAQ:VRDN opened at $15.46 on Tuesday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 18.55 and a current ratio of 18.55. The company has a market capitalization of $1.26 billion, a P/E ratio of -3.59 and a beta of 1.05. The stock’s 50 day moving average price is $16.98 and its 200 day moving average price is $19.77. Viridian Therapeutics, Inc. has a 52 week low of $11.40 and a 52 week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.24. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The company had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.05 million. On average, research analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on VRDN. Royal Bank of Canada lifted their price objective on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 17th. Needham & Company LLC reissued a “buy” rating and set a $38.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, January 7th. HC Wainwright reissued a “buy” rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research note on Monday, December 16th. Wells Fargo & Company reaffirmed an “equal weight” rating and set a $27.00 target price (down previously from $37.00) on shares of Viridian Therapeutics in a research note on Thursday, December 19th. Finally, TD Cowen began coverage on shares of Viridian Therapeutics in a report on Monday, November 25th. They set a “buy” rating for the company. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.70.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.